These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 10332569)

  • 1. Dihydrotestosterone: a rationale for its use as a non-aromatizable androgen replacement therapeutic agent.
    Swerdloff RS; Wang C
    Baillieres Clin Endocrinol Metab; 1998 Oct; 12(3):501-6. PubMed ID: 10332569
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The androgen control of sebum production. Studies of subjects with dihydrotestosterone deficiency and complete androgen insensitivity.
    Imperato-McGinley J; Gautier T; Cai LQ; Yee B; Epstein J; Pochi P
    J Clin Endocrinol Metab; 1993 Feb; 76(2):524-8. PubMed ID: 8381804
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety aspects of androgen treatment with 5alpha-dihydrotestosterone.
    Sakhri S; Gooren LJ
    Andrologia; 2007 Dec; 39(6):216-22. PubMed ID: 18076420
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Negative Impact of Testosterone Deficiency and 5α-Reductase Inhibitors Therapy on Metabolic and Sexual Function in Men.
    Traish AM
    Adv Exp Med Biol; 2017; 1043():473-526. PubMed ID: 29224108
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of aromatizable and unaromatizable androgen replacement in hypogonadal men on GH responsiveness.
    Gleeson HK; Shalet SM
    Clin Endocrinol (Oxf); 2009 Jan; 70(1):109-15. PubMed ID: 18549466
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transdermal dihydrotestosterone treatment of 'andropause'.
    de Lignieres B
    Ann Med; 1993 Jun; 25(3):235-41. PubMed ID: 7687444
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Three-month treatment with a long-acting gonadotropin-releasing hormone agonist of patients with benign prostatic hyperplasia: effects on tissue androgen concentration, 5 alpha-reductase activity and androgen receptor content.
    Forti G; Salerno R; Moneti G; Zoppi S; Fiorelli G; Marinoni T; Natali A; Costantini A; Serio M; Martini L
    J Clin Endocrinol Metab; 1989 Feb; 68(2):461-8. PubMed ID: 2465302
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Androgen-induced regrowth in the castrated rat ventral prostate: role of 5alpha-reductase.
    Wright AS; Douglas RC; Thomas LN; Lazier CB; Rittmaster RS
    Endocrinology; 1999 Oct; 140(10):4509-15. PubMed ID: 10499505
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential effect of finasteride on the tissue androgen concentrations in benign prostatic hyperplasia.
    Habib FK; Ross M; Tate R; Chisholm GD
    Clin Endocrinol (Oxf); 1997 Feb; 46(2):137-44. PubMed ID: 9135694
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intraprostatic testosterone and dihydrotestosterone. Part II: concentrations after androgen hormonal manipulation in men with benign prostatic hyperplasia and prostate cancer.
    van der Sluis TM; Meuleman EJ; van Moorselaar RJ; Bui HN; Blankenstein MA; Heijboer AC; Vis AN
    BJU Int; 2012 Jan; 109(2):183-8. PubMed ID: 21992404
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term effects of dihydrotestosterone treatment on prostate growth in healthy, middle-aged men without prostate disease: a randomized, placebo-controlled trial.
    Idan A; Griffiths KA; Harwood DT; Seibel MJ; Turner L; Conway AJ; Handelsman DJ
    Ann Intern Med; 2010 Nov; 153(10):621-32. PubMed ID: 21079217
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Possible mechanisms of androgen resistance in 5 alpha-reductase deficiency: implications for the physiological roles of 5 alpha-reductases.
    Hodgins MB
    J Steroid Biochem; 1983 Jul; 19(1B):555-9. PubMed ID: 6887883
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma levels of dihydrotestosterone remain in the normal range in men treated with long-acting parenteral testosterone undecanoate.
    Yassin AA; Saad F
    Andrologia; 2007 Oct; 39(5):181-4. PubMed ID: 17714216
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prolactin influences upon androgen action in male accessory sex organs.
    Thomas JA; Keenan EJ
    Adv Sex Horm Res; 1976; 2():425-70. PubMed ID: 189591
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The non-aromatizable androgen, dihydrotestosterone, induces antiestrogenic responses in the rainbow trout.
    Shilling AD; Williams DE
    J Steroid Biochem Mol Biol; 2000 Nov; 74(4):187-94. PubMed ID: 11162924
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiac concentric remodelling induced by non-aromatizable (dihydro-)testosterone is antagonized by oestradiol in ovariectomized rats.
    Tivesten A; Bollano E; Nyström HC; Alexanderson C; Bergström G; Holmäng A
    J Endocrinol; 2006 Jun; 189(3):485-91. PubMed ID: 16731780
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of dihydrotestosterone in benign prostatic hyperplasia.
    Carson C; Rittmaster R
    Urology; 2003 Apr; 61(4 Suppl 1):2-7. PubMed ID: 12657354
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Androgen replacement therapy: present and future.
    Gooren LJ; Bunck MC
    Drugs; 2004; 64(17):1861-91. PubMed ID: 15329035
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bone and mineral metabolism in aged male rats: short and long term effects of androgen deficiency.
    Vanderschueren D; Van Herck E; Suiker AM; Visser WJ; Schot LP; Bouillon R
    Endocrinology; 1992 May; 130(5):2906-16. PubMed ID: 1572302
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of diethylstilbestrol and medroxyprogesterone acetate on kinetics and production of testosterone and dihydrotestosterone in patients with prostatic carcinoma.
    Nolten WE; Sholiton LJ; Srivastava LS; Knowles HC; Werk EE
    J Clin Endocrinol Metab; 1976 Dec; 43(6):1226-33. PubMed ID: 1002814
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.